Literature DB >> 20179698

Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection.

David Nunes1, Catherine Fleming, Gwynneth Offner, Donald Craven, Oren Fix, Timothy Heeren, Margaret J Koziel, Camilla Graham, Sheila Tumilty, Paul Skolnik, Sherri Stuver, C Robert Horsburgh, Deborah Cotton.   

Abstract

OBJECTIVES: Noninvasive markers of liver fibrosis correlate with the stage of liver fibrosis, but have not been widely applied to predict liver-related mortality.
METHODS: We assessed the ability of two indices of liver fibrosis, aspartate aminotransferase (AST)-to-platelet ratio index (APRI) and Fib-4, and two markers of extracellular matrix metabolism, hyaluronic acid (HA) and YKL40, to predict liver mortality in a prospective cohort of hepatitis C virus (HCV)-infected individuals with and without HIV coinfection. These were compared with two established prognostic scores, the Child-Pugh-Turcotte (CPT) and model of end-stage liver disease (MELD) scores.
RESULTS: A total of 303 subjects, of whom 207 were HIV positive at study entry, were followed up for a mean period of 3.1 years. There were 33 deaths due to liver disease. The ability of each test and score to predict 3-year liver mortality was expressed as the area under the receiver operator curve. The area under the receiver operator curve 95% confidence intervals were: HA 0.92 (0.86-0.96), CPT 0.91 (0.79-0.96), APRI 0.88 (0.80-0.93), Fib-4 0.87 (0.77-0.92), MELD 0.84 (71-0.91). In multivariate analyses HA, APRI, and fib-4 were independent predictors of mortality when included in models with MELD or CPT.
CONCLUSION: Noninvasive markers of liver fibrosis are highly predictive of liver outcome in HCV-infected individuals with and without HIV coinfection. These markers seem to have a prognostic value independent of CPT and MELD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179698     DOI: 10.1038/ajg.2009.746

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  49 in total

1.  Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.

Authors:  Daniel L Motola; Peter Caravan; Raymond T Chung; Bryan C Fuchs
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

2.  Prognostic value of liver fibrosis biomarkers: a meta-analysis.

Authors:  Thierry Poynard; Yen Ngo; Hugo Perazzo; Mona Munteanu; Pascal Lebray; Joseph Moussalli; Dominique Thabut; Yves Benhamou; Vlad Ratziu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-07

3.  Noninvasive serum models to predict significant liver related events in chronic hepatitis C.

Authors:  Ragesh Babu Thandassery; Saad Al Kaabi; Madiha E Soofi; Benjamin Tharian; Rajvir Singh
Journal:  Hepatol Int       Date:  2017-06-20       Impact factor: 6.047

4.  Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.

Authors:  Heidi M Crane; Robin M Nance; Susan R Heckbert; Corey Ritchings; Lisa Rosenblatt; Matthew Budoff; Brian R Wood; David L Tirschwell; H Nina Kim; William C Mathews; Elvin Geng; Richard D Moore; Peter W Hunt; Joseph J Eron; Greer A Burkholder; Daniel R Drozd; Felicia C Chow; Kyra J Becker; Joseph R Zunt; Emily L Ho; Rizwan Kalani; Andrew Huffer; Bridget M Whitney; Michael S Saag; Mari M Kitahata; Joseph A C Delaney
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

5.  Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma.

Authors:  Hung-Hsu Hung; Chien-Wei Su; Chiung-Ru Lai; Gar-Yang Chau; Che-Chang Chan; Yi-Hsiang Huang; Teh-Ia Huo; Pui-Ching Lee; Wei-Yu Kao; Shou-Dong Lee; Jaw-Ching Wu
Journal:  Hepatol Int       Date:  2010-09-24       Impact factor: 6.047

6.  Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients.

Authors:  Joseph K Lim; Janet P Tate; Shawn L Fultz; Joseph L Goulet; Joseph Conigliaro; Kendall J Bryant; Adam J Gordon; Cynthia Gibert; David Rimland; Matthew Bidwell Goetz; Marina B Klein; David A Fiellin; Amy C Justice; Vincent Lo Re
Journal:  Clin Infect Dis       Date:  2014-02-25       Impact factor: 9.079

7.  Reply to Post and Sabin.

Authors:  Jennifer Price; Chloe Thio
Journal:  J Infect Dis       Date:  2012-10-29       Impact factor: 5.226

8.  Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Shuya Matsuda; Masaru Muraoka; Yutaka Yasui; Shoko Suzuki; Takanori Hosokawa; Ken Ueda; Kaoru Tsuchiya; Hiroyuki Nakanishi; Jun Itakura; Yuka Takahashi; Yasuhiro Asahina; Namiki Izumi
Journal:  J Gastroenterol       Date:  2013-12-15       Impact factor: 7.527

Review 9.  Chronic hepatitis C and liver fibrosis.

Authors:  Giada Sebastiani; Konstantinos Gkouvatsos; Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

10.  Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems.

Authors:  Daniel Fuster; Judith I Tsui; Debbie M Cheng; Emily K Quinn; Kaku A Armah; David Nunes; Matthew S Freiberg; Jeffrey H Samet
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-17       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.